1 Stacchiotti, S. et al. Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. Ann Oncol28, 1230-1242, doi:10.1093/annonc/mdx054 (2017).
2 Zhou, J. et al. Prognostic Factors in Patients With Spinal Chordoma: An Integrative Analysis of 682 Patients. Neurosurgery81, 812-823, doi:10.1093/neuros/nyx081 (2017).
3 Whelan, J. S. & Davis, L. E. Osteosarcoma, Chondrosarcoma, and Chordoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology36, 188-193, doi:10.1200/jco.2017.75.1743 (2018).
4 Sharifnia, T. et al. Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nat Med25, 292-300, doi:10.1038/s41591-018-0312-3 (2019).
5 van Wulfften Palthe, O. D. R. et al. Sacral chordoma: a clinical review of 101 cases with 30-year experience in a single institution. The spine journal : official journal of the North American Spine Society19, 869-879, doi:10.1016/j.spinee.2018.11.002 (2019).
6 Nepomuceno, T. C. et al. PALB2 Variants: Protein Domains and Cancer Susceptibility. Trends in cancer7, 188-197, doi:10.1016/j.trecan.2020.10.002 (2021).
7 Ducy, M. et al. The Tumor Suppressor PALB2: Inside Out. Trends in biochemical sciences44, 226-240, doi:10.1016/j.tibs.2018.10.008 (2019).
8 Yang, X. et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of clinical oncology : official journal of the American Society of Clinical Oncology38, 674-685, doi:10.1200/jco.19.01907 (2020).
9 Rantakari, P. et al. Inactivation of Palb2 gene leads to mesoderm differentiation defect and early embryonic lethality in mice. Human molecular genetics19, 3021-3029, doi:10.1093/hmg/ddq207 (2010).
10 Li, J., Li, M., Chen, P. & Ba, Q. High expression of PALB2 predicts poor prognosis in patients with advanced breast cancer. FEBS Open Bio8, 56-63, doi:10.1002/2211-5463.12356 (2018).
11 al-Mefty, O. & Borba, L. A. Skull base chordomas: a management challenge. J Neurosurg86, 182-189, doi:10.3171/jns.1997.86.2.0182 (1997).
12 Zhai, Y. et al. A nomogram to predict the progression-free survival of clival chordoma. J Neurosurg, 1-9, doi:10.3171/2019.10.JNS192414 (2019).
13 Zou, Y. et al. Prognostic Factors in Clival Chordomas: An Integrated Analysis of 347 Patients. World Neurosurg118, e375-e387, doi:10.1016/j.wneu.2018.06.194 (2018).
14 Li, M. et al. SNF5 as a prognostic factor in skull base chordoma. J Neurooncol137, 139-146, doi:10.1007/s11060-017-2706-3 (2018).
15 Zhai, Y. et al. Analysis of clinical factors and PDGFR-beta in predicting prognosis of patients with clival chordoma. J Neurosurg129, 1429-1437, doi:10.3171/2017.6.JNS17562 (2018).
16 Zhang, S. et al. Predictive Value of Transforming Growth Factor-alpha and Ki-67 for the Prognosis of Skull Base Chordoma. World Neurosurg129, e199-e206, doi:10.1016/j.wneu.2019.05.110 (2019).
17 Lv, G. H. et al. Clinicopathological and Prognostic Characteristics in Extra-Axial Chordomas: An Integrative Analysis of 86 Cases and Comparison With Axial Chordomas. Neurosurgery85, E527-e542, doi:10.1093/neuros/nyz073 (2019).
18 Konakondla, S. et al. Maximizing Sacral Chordoma Resection by Precise 3-Dimensional Tumor Modeling in the Operating Room Using Intraoperative Computed Tomography Registration with Preoperative Magnetic Resonance Imaging Fusion and Intraoperative Neuronavigation: A Case Series. World Neurosurg125, e1125-e1131, doi:10.1016/j.wneu.2019.01.257 (2019).
19 Antoniou, A. C. et al. Breast-cancer risk in families with mutations in PALB2. The New England journal of medicine371, 497-506, doi:10.1056/NEJMoa1400382 (2014).
20 Velázquez, C. et al. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer. Breast (Edinburgh, Scotland)43, 91-96, doi:10.1016/j.breast.2018.11.010 (2019).
21 Bai, J. et al. Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival. Nat Commun12, 757, doi:10.1038/s41467-021-21026-5 (2021).
22 Ahlskog, J. K., Larsen, B. D., Achanta, K. & Sørensen, C. S. ATM/ATR-mediated phosphorylation of PALB2 promotes RAD51 function. EMBO Rep17, 671-681, doi:10.15252/embr.201541455 (2016).
23 Buisson, R. et al. Coupling of Homologous Recombination and the Checkpoint by ATR. Molecular cell65, 336-346, doi:10.1016/j.molcel.2016.12.007 (2017).
24 Orthwein, A. et al. A mechanism for the suppression of homologous recombination in G1 cells. Nature528, 422-426, doi:10.1038/nature16142 (2015).
25 Karachaliou, N. et al. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer14, 304-310, doi:10.1016/j.jtho.2018.10.168 (2019).